1
|
Saloner R, VandeVrede L, Asken BM, Paolillo EW, Gontrum EQ, Wolf A, Lario‐Lago A, Milà‐Alomà M, Triana‐Baltzer G, Kolb HC, Dubal DB, Rabinovici GD, Miller BL, Boxer AL, Casaletto KB, Kramer JH. Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults. Alzheimers Dement 2024; 20:376-387. [PMID: 37639492 PMCID: PMC10843677 DOI: 10.1002/alz.13454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 08/04/2023] [Accepted: 08/07/2023] [Indexed: 08/31/2023]
Abstract
INTRODUCTION Accumulating evidence indicates disproportionate tau burden and tau-related clinical progression in females. However, sex differences in plasma phosphorylated tau (p-tau)217 prediction of subclinical cognitive and brain changes are unknown. METHODS We measured baseline plasma p-tau217, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) in 163 participants (85 cognitively unimpaired [CU], 78 mild cognitive impairment [MCI]). In CU, linear mixed effects models examined sex differences in plasma biomarker prediction of longitudinal domain-specific cognitive decline and brain atrophy. Cognitive models were repeated in MCI. RESULTS In CU females, baseline plasma p-tau217 predicted verbal memory and medial temporal lobe trajectories such that trajectories significantly declined once p-tau217 concentrations surpassed 0.053 pg/ml, a threshold that corresponded to early levels of cortical amyloid aggregation in secondary amyloid positron emission tomography analyses. CU males exhibited similar rates of cognitive decline and brain atrophy, but these trajectories were not dependent on plasma p-tau217. Plasma GFAP and NfL exhibited similar female-specific prediction of medial temporal lobe atrophy in CU. Plasma p-tau217 exhibited comparable prediction of cognitive decline across sex in MCI. DISCUSSION Plasma p-tau217 may capture earlier Alzheimer's disease (AD)-related cognitive and brain atrophy hallmarks in females compared to males, possibly reflective of increased susceptibility to AD pathophysiology.
Collapse
Affiliation(s)
- Rowan Saloner
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Lawren VandeVrede
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Breton M. Asken
- Department of Clinical and Health PsychologyUniversity of FloridaGainesvilleFloridaUSA
| | - Emily W. Paolillo
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Eva Q. Gontrum
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Amy Wolf
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Argentina Lario‐Lago
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Marta Milà‐Alomà
- Department of Radiology and Biomedical ImagingUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | | | - Hartmuth C. Kolb
- Neuroscience BiomarkersJanssen Research & Development, LLCSan DiegoCaliforniaUSA
| | - Dena B. Dubal
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Gil D. Rabinovici
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
- Department of Radiology and Biomedical ImagingUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Bruce L. Miller
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Adam L. Boxer
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Kaitlin B. Casaletto
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Joel H. Kramer
- Department of NeurologyWeill Institute for NeurosciencesUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| |
Collapse
|
2
|
Suárez‐Calvet M, Ashton NJ, Puig‐Pijoan A, Milà‐Alomà M, Fernández‐Lebrero A, García‐Escobar G, González‐Ortiz F, Kac PR, Brum WS, Benedet AL, Rodriguez JL, Day TA, Dage JL, Vanbrabant J, Stoops E, Vanmechelen E, Triana‐Baltzer G, Moughadam S, Kolb HC, Ortiz‐Romero P, Karikari TK, Minguillón C, Sánchez JJH, Navalpotro‐Gómez I, Grau‐Rivera O, Manero RM, Puente‐Periz V, de la Torre R, Roquer J, Zetterberg H, Blennow K. A head‐to‐head comparison of plasma phosphorylated tau assays in the real‐world memory clinic. Alzheimers Dement 2022. [DOI: 10.1002/alz.065391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Marc Suárez‐Calvet
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Servei de Neurologia, Hospital del Mar Barcelona Spain
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) Madrid Spain
| | - Nicholas J. Ashton
- NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation London United Kingdom
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg Mölndal Sweden
- Wallenberg Centre for Molecular and Translational Medicine; University of Gothenburg Gothenburg Sweden
- King’s College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute London United Kingdom
| | - Albert Puig‐Pijoan
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Servei de Neurologia, Hospital del Mar Barcelona Spain
- Department of Medicine, Universitat Autònoma de Barcelona Barcelona Spain
| | - Marta Milà‐Alomà
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) Madrid Spain
- Universitat Pompeu Fabra Barcelona Spain
| | | | - Greta García‐Escobar
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Servei de Neurologia, Hospital del Mar Barcelona Spain
| | - Fernándo González‐Ortiz
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg Mölndal Sweden
| | - Przemyslaw Radoslaw Kac
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg Mölndal Sweden
| | - Wagner Scheeren Brum
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg Mölndal Sweden
- Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
| | - Andréa Lessa Benedet
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg Mölndal Sweden
| | - Juan Lantero Rodriguez
- Institute of Neuroscience & Physiology, Department of Psychiatry & Neurochemistry, The Sahlgrenska Academy, University of Gothenburg Mölndal Sweden
| | - Theresa A. Day
- Lilly Research Laboratories, Eli Lilly and Company Indianapolis IN USA
| | - Jeffrey L. Dage
- Stark Neurosciences Research Institute, Indiana University School of Medicine Indianapolis IN USA
- Eli Lilly and Company Indianapolis IN USA
| | | | - Erik Stoops
- ADx NeuroSciences NV, Technologiepark 94 Ghent 9052 Belgium
| | | | | | | | | | - Paula Ortiz‐Romero
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain
| | - Thomas K Karikari
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg Mölndal Sweden
| | - Carolina Minguillón
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) Madrid Spain
| | | | - Irene Navalpotro‐Gómez
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Servei de Neurologia, Hospital del Mar Barcelona Spain
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
| | - Oriol Grau‐Rivera
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Servei de Neurologia, Hospital del Mar Barcelona Spain
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) Madrid Spain
| | - Rosa María Manero
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Servei de Neurologia, Hospital del Mar Barcelona Spain
| | - Víctor Puente‐Periz
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Servei de Neurologia, Hospital del Mar Barcelona Spain
| | - Rafael de la Torre
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Universitat Pompeu Fabra Barcelona Spain
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) Madrid Spain
| | - Jaume Roquer
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Servei de Neurologia, Hospital del Mar Barcelona Spain
- Department of Medicine, Universitat Autònoma de Barcelona Barcelona Spain
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg Mölndal Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital Mölndal Sweden
- Hong Kong Center for Neurodegenerative Diseases Clear Water Bay Hong Kong
- Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square London United Kingdom
- UK Dementia Research Institute at UCL London United Kingdom
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg Mölndal Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital Mölndal Sweden
| |
Collapse
|
3
|
Doré V, Doecke JD, Saad ZS, Triana‐Baltzer G, Slemmon R, Krishnadas N, Bourgeat P, Huang K, Burnham S, Fowler C, Rainey‐Smith SR, Bush AI, Ward L, Robertson J, Martins RN, Masters CL, Villemagne VL, Fripp J, Kolb HC, Rowe CC. Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. Alz & Dem Diag Ass & Dis Mo 2022; 14:e12307. [PMID: 35415202 PMCID: PMC8984092 DOI: 10.1002/dad2.12307] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Accepted: 03/06/2022] [Indexed: 11/11/2022]
Abstract
Introduction We evaluated a new Simoa plasma assay for phosphorylated tau (P‐tau) at aa217 enhanced by additional p‐tau sites (p217+tau). Methods Plasma p217+tau levels were compared to 18F‐NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and 18F‐MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU) participants. Results Compared to Aβ− CU, the plasma levels of p217+tau increased 2‐fold in Aβ+ CU and 3.5‐fold in Aβ+ CI. In Aβ− the p217+tau levels did not differ significantly between CU and CI. P217+tau correlated with Aβ centiloids P = .67 (CI, P = .64; CU, P = .45) and tau SUVRMTP = .63 (CI, P = .69; CU, P = .34). Area under curve (AUC) for Alzheimer's disease (AD) dementia versus Aβ− CU was 0.94, for AD dementia versus other dementia was 0.93, for Aβ+ versus Aβ− PET was 0.89, and for tau+ versus tau− PET was 0.89. Discussion Plasma p217+tau levels elevate early in the AD continuum and correlate well with Aβ and tau PET.
Collapse
Affiliation(s)
- Vincent Doré
- The Australian e‐Health Research Centre CSIRO Melbourne Victoria Australia
- Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
| | - James D. Doecke
- The Australian e‐Health Research Centre CSIRO Brisbane Queensland Australia
| | - Ziad S. Saad
- Neuroscience Biomarkers Janssen Research and Development La Jolla California USA
| | | | - Randy Slemmon
- Neuroscience Biomarkers Janssen Research and Development La Jolla California USA
| | - Natasha Krishnadas
- Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
| | - Pierrick Bourgeat
- The Australian e‐Health Research Centre CSIRO Brisbane Queensland Australia
| | - Kun Huang
- Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
| | - Samantha Burnham
- The Australian e‐Health Research Centre CSIRO Melbourne Victoria Australia
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
| | | | - Ashley I. Bush
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
- Florey Department of Neuroscience and Mental Health The University of Melbourne Melbourne Victoria Australia
| | - Larry Ward
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
| | - Jo Robertson
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
| | - Ralph N. Martins
- Edith Cowan University Joondalup Western Australia Australia
- Centre for Healthy Ageing, Health Futures Institute Murdoch University Murdoch Western Australia Australia
- McCusker Alzheimer's Research Foundation Nedlands Western Australia Australia
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
| | - Victor L. Villemagne
- Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
- Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA
| | - Jurgen Fripp
- The Australian e‐Health Research Centre CSIRO Brisbane Queensland Australia
| | - Hartmuth C. Kolb
- Neuroscience Biomarkers Janssen Research and Development La Jolla California USA
| | - Christopher C. Rowe
- Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
- Florey Department of Neuroscience and Mental Health The University of Melbourne Melbourne Victoria Australia
| |
Collapse
|
4
|
Rowe CC, Doecke JD, Saad ZS, Triana‐Baltzer G, Slemmon JR, Krishnadas N, Fowler CJ, Rainey‐Smith SR, Ward L, Robertson J, Martins RN, Fripp J, Masters CL, Villemagne VL, Kolb HC, Dore V. Plasma p217+tau concordance with
18
F‐NAV4694 beta‐amyloid and
18
F‐MK6240 tau PET in mild Alzheimer’s disease and cognitively unimpaired participants in the AIBL/ADNeT cohort. Alzheimers Dement 2021. [DOI: 10.1002/alz.055706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Christopher C. Rowe
- The Florey Department of Neuroscience and Mental Health, The University of Melbourne Melbourne VIC Australia
- Australian Dementia Network (ADNeT) Melbourne Australia
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| | - James D. Doecke
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Ziad S. Saad
- Janssen Research and Development LLC San Diego CA USA
| | | | | | - Natasha Krishnadas
- Florey Department of Neuroscience and Mental Health, University of Melbourne Melbourne VIC Australia
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| | - Christopher J. Fowler
- Florey Institute of Neuroscience and Mental Health Melbourne Melbourne VIC Australia
| | | | - Larry Ward
- The University of Melbourne Parkville VIC Australia
| | - Joanne Robertson
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne Parkville VIC Australia
| | - Ralph N. Martins
- Co‐operative research Centre (CRC) for Mental Health Carlton South VIC Australia
- Department of Biomedical Sciences, Macquarie University Macquarie Park NSW Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Colin L. Masters
- Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | | | | | - Vincent Dore
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
- Austin Health Melbourne Australia
| |
Collapse
|